{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:38:05Z","timestamp":1773085085678,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3699,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p>Gatifloxacin, a fluoroquinolone with extended gram\u2010positive activity, has become extensively used in both the community and hospital environments. Unfortunately, concerns have been raised about the use of certain fluoroquinolones because of adverse drug reactions. A 44\u2010year\u2010old woman developed acute hepatitis while receiving gatifloxacin for chronic sinusitis. After 5 days of receiving antibiotics, the patient developed nausea, lethargy, and abdominal pain, all of which progressed over the next few days. Liver function tests were elevated, with bilirubin peaking at 9.4 mg\/dl. The patient also became jaundiced. A percutaneous liver biopsy showed acute hepatitis with eosinophilic infiltrates consistent with drug\u2010induced hepatitis. All other drugs and disease processes were ruled out as likely causes of the patient's hepatitis. Clinicians should be alerted to the possibility that hepatitis may occur with gatifloxacin administration.<\/jats:p>","DOI":"10.1592\/phco.21.20.1579.34479","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T05:27:33Z","timestamp":1086758853000},"page":"1579-1582","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Gatifloxacin\u2010Associated Acute Hepatitis"],"prefix":"10.1002","volume":"21","author":[{"given":"Neil E.","family":"Henann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Zambie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.1.35.34440"},{"key":"e_1_2_1_3_2","volume-title":"Zagam (sparfloxacin) package insert","author":"Rh\u00f4ne\u2010Poulenc Rorer Pharmaceutical Inc.","year":"1996"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420517"},{"key":"e_1_2_1_5_2","volume-title":"Trovan (trovafloxacin) package insert","author":"Pfizer Inc.","year":"2000"},{"issue":"11","key":"e_1_2_1_6_2","first-page":"S70","article-title":"Safety and tolerability of gatifloxacin, an advanced\u2010generation, 8\u2010methoxy fluoroquinolone","volume":"20","author":"Breen J","year":"1999","journal-title":"J Resp Dis"},{"key":"e_1_2_1_7_2","first-page":"1221","volume-title":"Sleisenger & Fordtran's gastrointestinal and liver disease","author":"Farrell GC","year":"1998"},{"key":"e_1_2_1_8_2","first-page":"317","article-title":"Drug\u2010induced liver disorders: report of an international consensus meeting. Standardization of definitions and criteria of causality assessment of adverse drug reactions","volume":"28","author":"B\u00e9nichou C, for the Council for International Organizations of Medical Sciences.","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_1_9_2","first-page":"347","article-title":"Practice guidelines for the management of community\u2010acquired pneumonia. Guidelines from the Infectious Diseases Society of America. Clin. Infect.","volume":"31","author":"Bartlett JG","year":"2000","journal-title":"Dis."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.7.at1010"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-61013-4_20"},{"key":"e_1_2_1_12_2","volume-title":"Silver","author":"Anonymous.","year":"1974"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90125-B"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199109000-00027"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.1979.03300070019017","article-title":"An algorithm for the operational assessment of adverse drug reactions","volume":"242","author":"Kramer MS","year":"1979","journal-title":"JAMA"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.20.1579.34479","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.20.1579.34479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:30:03Z","timestamp":1761067803000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.20.1579.34479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1592\/phco.21.20.1579.34479"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.20.1579.34479","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}